#United States #New York #Pomerantz LLP #FDA Response #Grace Therapeutics

Pomerantz Law Firm Investigates Grace Therapeutics (NASDAQ: GRCE)

In a bold move to protect investors, Pomerantz LLP has launched an investigation concerning potential securities fraud related to Grace Therapeutics, Inc. This inquiry comes on the heels of a dramatic drop in the company's stock price following a disappointing FDA announcement.

On April 23, 2026, Grace Therapeutics issued a press release revealing a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for GTx-104. This drug was aimed at treating patients suffering from aneurysmal subarachnoid hemorrhage (aSAH).

The CRL outlined significant concerns, particularly in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of the application. Specifically, it highlighted issues surrounding leachables data for product packaging, toxicology risk assessments related to the product, and various manufacturing deficiencies found at the company’s contract manufacturing organization. The release of this unfavorable information caused Grace's stock to plummet by $1.96, equating to a staggering 45.48% decrease, closing at just $2.35 per share.

The impact of this news on investors was immediate and severe, prompting Pomerantz LLP to take action on behalf of those affected. The firm's investigation seeks to determine whether Grace, along with specific officers and directors, engaged in securities fraud or other unlawful business practices leading up to this drastic decline in stock value.

Pomerantz LLP, with a historical reputation in the realm of corporate, securities, and antitrust class litigation, has been at the forefront of fighting against practices that undermine shareholder rights. Founded by the late Abraham L. Pomerantz, a pioneer in the class action legal arena, the firm has a legacy of recovering substantial financial recompense for victims of corporate misconduct. Their dedication extends to ensuring that similar struggles do not fall into silence, continuing to uphold the rights of investors over 85 years after its inception.

As the investigation progresses, Pomerantz encourages investors of Grace Therapeutics who are affected by this incident to reach out for consultation. Danielle Peyton of Pomerantz is available to discuss the potential for a class action lawsuit and provide further insights into the legalities surrounding the recent developments.

In these trying times for Grace Therapeutics, stakeholders can remain proactive by understanding their rights and the measures they can take in light of these unforeseen circumstances. The firm remains steadfast in its commitment to uncovering the truth and striving for justice for those affected.

Investors are advised to keep informed about the progress of the investigation, as developments may significantly influence financial outcomes and corporate accountability. With transparency being a cornerstone of trust, Pomerantz LLP aims to provide clarity amidst the turmoil surrounding Grace Therapeutics and ensure investors’ voices are heard.

For more information regarding this investigation, available resources, and advice on how to proceed, affected investors are urged to contact Pomerantz LLP directly.